Those of us in rare disease communities have learned one lesson particularly well: We all must listen to our bodies. That’s why a celebration like National Relaxation Day — which happens to be Aug. 15, the day this column was published — is such an apt reminder. Many will…
Read more
A study found that changes in immune cell metabolism may underlie increases in inflammatory signaling molecules in people with pulmonary arterial hypertension (PAH), suggesting that targeting immune cell metabolism could be a treatment strategy for the condition. The study, “Metabolic changes of peripheral blood mononuclear cells…
Tectonic Therapeutic plans to launch a Phase 2 clinical trial to test the impact of its therapy candidate TX45 on blood flow, or hemodynamics, in people with pulmonary hypertension and interstitial lung disease (PH-ILD). The move comes on the heels of positive results from part A of a…
Get regular updates to your inbox.
